Evidence map›Paper›PMID 35251370›Full record

ArticleDisease markers2022

CD38 Expression by Circulating and Skin-Infiltrating Lymphocytes from Sezary Syndrome Patients: A Flow Cytometry and Immunohistochemistry Study.

Pietro Quaglino, Mauro Novelli, Paolo Fava, Erika Ortolan, Chiara Astrua, Luca Tonella, Carlo Francesco Tomasini, Rebecca Senetta, Simone Ribero, Renata Ponti and 2 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Disease markers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Pietro QuaglinoDermatologic Clinic, Department of Medical Sciences, University of Turin Medical School, Torino, Italy.ORCID https://orcid.org/0000-0003-4185-9586
Mauro NovelliDermatologic Clinic, Department of Medical Sciences, University of Turin Medical School, Torino, Italy.
Paolo FavaDermatologic Clinic, Department of Medical Sciences, University of Turin Medical School, Torino, Italy.ORCID https://orcid.org/0000-0002-8443-7458
Erika OrtolanLaboratory of Immunogenetics, Department of Medical Sciences, University of Torino, 10126 Torino, Italy.ORCID https://orcid.org/0000-0003-2287-9020
Chiara AstruaDermatologic Clinic, Department of Medical Sciences, University of Turin Medical School, Torino, Italy.
Luca TonellaDermatologic Clinic, Department of Medical Sciences, University of Turin Medical School, Torino, Italy.ORCID https://orcid.org/0000-0001-6790-554X
Carlo Francesco TomasiniIRCCS Fondazione Policlinico San Matteo, Department of Medical-Surgical, Diagnostic and Pediatric Sciences, Dermatologic Clinic, University of Pavia School of Medicine, Pavia, Italy.
Rebecca SenettaDepartment of Oncology, Pathology Unit, University of Turin, 10126 Turin, Italy.ORCID https://orcid.org/0000-0001-8419-4591
Simone RiberoDermatologic Clinic, Department of Medical Sciences, University of Turin Medical School, Torino, Italy.ORCID https://orcid.org/0000-0002-0098-1406
Renata PontiDermatologic Clinic, Department of Medical Sciences, University of Turin Medical School, Torino, Italy.
Maria Teresa FierroDermatologic Clinic, Department of Medical Sciences, University of Turin Medical School, Torino, Italy.ORCID https://orcid.org/0000-0003-0996-6322
Ada FunaroLaboratory of Immunogenetics, Department of Medical Sciences, University of Torino, 10126 Torino, Italy.ORCID https://orcid.org/0000-0001-6341-1817
University of Turin · ITUniversity of Pavia · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundReports on the expression of CD38 in Sézary syndrome (SS), erythrodermic primary cutaneous T cell lymphoma with leukemic involvement, are limited. The aim of the present study is the analysis of the expression of CD38 by skin-infiltrating mononuclear cells and circulating T lymphocytes in a cohort of SS patients.

methodsSS patients diagnosed since 1985 in our clinic were retrospectively analyzed for CD38 expression in biopsy and blood samples by immunohistochemistry and flow cytometry, respectively.

resultsSS patients show a predominant CD38-negative phenotype on both skin and blood. A subgroup of patients was found expressing CD38 (12 cases) in either the skin (>25% cell infiltrate) or blood (CD4+CD38+ >50%), among whom 4 in the blood, 7 in the skin, and 1 in both blood and skin.

conclusionThe implications of these observations may be twofold: the relevance in basic science is related to a potential role in immune defense regulation, whilst in perspective CD38 may become a target for antibody therapy, considering the availability of different anti-CD38 monoclonal antibodies.

Indexed as

Flow CytometryImmunohistochemistrySezary SyndromeSkin NeoplasmsADP-ribosyl Cyclase 1Biomarkers, TumorBiopsyCD4-Positive T-LymphocytesFemaleHumansLymphocyte CountMaleMembrane GlycoproteinsMiddle AgedRetrospective StudiesSkinADP-ribosyl Cyclase 1Biomarkers, TumorCD38 protein, humanMembrane Glycoproteins

Identifiers

PMID35251370
PMCPMC8896155
OpenAlexW4214655276

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.